ROIVANT SCIENCES LTD. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ROIVANT SCIENCES LTD. (ROIV) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.00% for the 12-month period ending 2025-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-05-20
- ROIVANT SCIENCES LTD. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2025 was 0.00%.
- ROIVANT SCIENCES LTD. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 0.00%.
- ROIVANT SCIENCES LTD. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was -2.00%.
- ROIVANT SCIENCES LTD. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was -1.66%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2025-03-31 | 0.00% 10-K · filed 2026-05-20 | |
| 2024-03-31 | 0.00% 10-K · filed 2026-05-20 | |
| 2023-03-31 | -2.00% 10-K · filed 2025-05-29 | -1.45% 10-K · filed 2023-06-28 |
| 2022-03-31 | -1.66% 10-K · filed 2023-06-28 | |
| 2021-03-31 | -12.40% 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |